Can a new model help botswana shield infants from RSV?

NCT ID NCT07756528

Ongoing Knowledge-focused Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This study aims to create a health economic model that estimates the costs and health benefits of different RSV prevention strategies for infants in Botswana. Researchers will gather input from policymakers, healthcare providers, funders, and other stakeholders through interviews, workshops, and surveys. The model is intended to help decision-makers understand whether and how to introduce RSV prevention tools, such as monoclonal antibodies. No RSV product will be tested in infants, and no medical treatment will be provided.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help Botswana's health leaders decide whether and how to introduce RSV prevention for infants, potentially reducing severe illness and hospitalizations.
What could go wrong: This is a modeling and engagement study, not a clinical test of an RSV product. The model's usefulness depends on data quality and stakeholder input, and it may not fully predict real-world outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RSV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RSV

Contacts and locations

Locations

Botswana Harvard Health Partnership

Gaborone, Gaborone, Botswana

More trials for these conditions

Other studies related to the condition(s) this trial covers.